Summary of patients who died after HSCT
| Patient ID . | Disease . | Remission at HSCT . | Donor . | Conditioning . | Onset to HSCT (d) . | Cause of death . |
|---|---|---|---|---|---|---|
| 07-01-001 | FHL3 | Complete | MUD | RT-MAC (Mel, dose na) | 108 | Reactivated HLH |
| 22-08-001 | FHL2 | No | MRD | RT-MAC (Treo 39 g/m2) | 115 | Infection |
| 22-09-002 | CHS | Complete | Haplo (post-Cy) | RT-MAC (Bu AUC 72 mg × h/L) | 45 | Infection |
| 22-16-001 | FHL2 | Complete | Haplo (CD3 depl) | RT-MAC (Treo 40 g/m2) | 95 | HSCT related |
| 22-22-003 | GS-2 | Complete | Haplo (αβ T depl) | RT-MAC (Treo 37 g/m2) | 95 | HSCT related |
| 22-28-001 | FHL3 | Complete | MMUD | RT-MAC (Treo 45 g/m2) | 131 | Infection |
| 22-35-001 | FHL3 | Partial | MMUD | RT-MAC (Treo 38 g/m2) | 60 | Persistent HLH |
| 26-03-008 | Undefined | na | Haplo (post-Cy) | RT-MAC (Bu, dose na) | na | Persistent HLH |
| 26-03-009 | FHL3 | na | Haplo (na) | na | na | na |
| Patient ID . | Disease . | Remission at HSCT . | Donor . | Conditioning . | Onset to HSCT (d) . | Cause of death . |
|---|---|---|---|---|---|---|
| 07-01-001 | FHL3 | Complete | MUD | RT-MAC (Mel, dose na) | 108 | Reactivated HLH |
| 22-08-001 | FHL2 | No | MRD | RT-MAC (Treo 39 g/m2) | 115 | Infection |
| 22-09-002 | CHS | Complete | Haplo (post-Cy) | RT-MAC (Bu AUC 72 mg × h/L) | 45 | Infection |
| 22-16-001 | FHL2 | Complete | Haplo (CD3 depl) | RT-MAC (Treo 40 g/m2) | 95 | HSCT related |
| 22-22-003 | GS-2 | Complete | Haplo (αβ T depl) | RT-MAC (Treo 37 g/m2) | 95 | HSCT related |
| 22-28-001 | FHL3 | Complete | MMUD | RT-MAC (Treo 45 g/m2) | 131 | Infection |
| 22-35-001 | FHL3 | Partial | MMUD | RT-MAC (Treo 38 g/m2) | 60 | Persistent HLH |
| 26-03-008 | Undefined | na | Haplo (post-Cy) | RT-MAC (Bu, dose na) | na | Persistent HLH |
| 26-03-009 | FHL3 | na | Haplo (na) | na | na | na |
AUC, area under the curve; Bu, busulfan; GS-2, Griscelli syndrome type 2; haplo, haploidentical; MMUD, mismatched unrelated donor; Mel, melphalan; MRD, matched related donor; MUD, matched unrelated donor; na, not available; RT-MAC, reduced-toxicity myeloablative conditioning; Treo, treosulfan.